Assessing the Real-World Safety of Regadenoson for Myocardial Perfusion Imaging: Insights from a Comprehensive Analysis of FAERS Data
Open Access
- 10 March 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1860
Abstract
Background/Objectives: Regadenoson, a selective adenosine A2A receptor agonist, is primarily prescribed for myocardial perfusion imaging (MPI). As its clinical use becomes more widespread in practice, assessing its safety in real-world settings is essential. Methods: In this research, disproportionality analysis was applied to evaluate the safety of Regadenoson by examining all adverse event (AE) reports since 2004 in the FDA Adverse Event Reporting System (FAERS), in which Regadenoson was identified as the primary suspected drug. The reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN) were used to analyze AEs associated with Regadenoson. The Weibull distribution was utilized to model the temporal risk of AEs. Results: The results confirmed some known adverse reactions, such as nausea, shortness of breath (dyspnea), palpitations/vomiting, headache, dizziness, chest pain, and flushing (facial redness or warmth), which were also listed on the drug’s label. New potential adverse reactions not mentioned in the label were identified, including micturition urgency, mental status changes, conversion disorder, eye movement disorder, and genital paraesthesia. This study highlighted the significance of monitoring AEs, particularly right after the start of Regadenoson administration. Conclusions: This study provides preliminary safety data on Regadenoson’s real-world use, corroborating known adverse effects while uncovering new potential risks. These findings offer valuable safety insights for clinicians when prescribing Regadenoson for the use of MPI.Keywords
Funding Information
- National Natural Science Foundation of China (82100439, 2024M751844, 2024M751839, ZR2023MH267, ZR2024QH242, ZR2022QH154, SDCX-ZG-202400144, KeyME-2021-05)
- China Postdoctoral Science Foundation (82100439, 2024M751844, 2024M751839, ZR2023MH267, ZR2024QH242, ZR2022QH154, SDCX-ZG-202400144, KeyME-2021-05)
- Natural Science Foundation of Shandong Province (82100439, 2024M751844, 2024M751839, ZR2023MH267, ZR2024QH242, ZR2022QH154, SDCX-ZG-202400144, KeyME-2021-05)
- Shandong Provincial Science and Technology Department Youth Science Fund Project (82100439, 2024M751844, 2024M751839, ZR2023MH267, ZR2024QH242, ZR2022QH154, SDCX-ZG-202400144, KeyME-2021-05)
- Shandong Postdoctoral Innovation Project (82100439, 2024M751844, 2024M751839, ZR2023MH267, ZR2024QH242, ZR2022QH154, SDCX-ZG-202400144, KeyME-2021-05)
- Key Laboratory of Medical Electrophysiology of Ministry of Education (Southwest Medical University) Open fund (82100439, 2024M751844, 2024M751839, ZR2023MH267, ZR2024QH242, ZR2022QH154, SDCX-ZG-202400144, KeyME-2021-05)
This publication has 37 references indexed in Scilit:
- Regadenoson for myocardial perfusion imaging: Is it safe?Journal of Nuclear Cardiology, 2014
- Erratum to: Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthmaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Regadenoson induced acute ST-segment elevation myocardial infarction and multivessel coronary thrombosisJournal of Nuclear Cardiology, 2013
- Acute Myocardial Infarction During Regadenoson Myocardial Perfusion ImagingPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- QTc prolongation after regadenoson administrationJournal of Nuclear Cardiology, 2012
- Regadenoson stress in patients with asthma and COPD: A breath of fresh airJournal of Nuclear Cardiology, 2012
- Seizures associated with regadenoson: A case seriesJournal of Nuclear Cardiology, 2011
- Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: Initial clinical experience in 1263 patientsJournal of Nuclear Cardiology, 2010
- The reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiology and Drug Safety, 2004
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001